IQ-AI LIMITED | Regulatory Story | |||
| Go to market news section | |||
|
IQ-AI Ltd
('IQ-AI' or the 'Company')
Conversion of Loan Notes - Correction
The announcement released by IQ-AI earlier today has been amended to correct the number of Ordinary Shares into which the CLNs may convert. The amended text of the announcement is set out below.
IQ-AI Ltd has received a conversion notice from Free Association Books Limited, converting £60,000 convertible loan notes and the £16,875 associated interest, issued on 18 November 2015, at a price of 1.15 pence, into 5,125,000 Ordinary Shares at a price of 1.15 pence per share ('Conversion'). Free Association Books Limited is a company in which Trevor Brown, who is an executive director of IQ-AI, has an interest.
Following the Conversion, Trevor Brown will be directly and indirectly interested in 43,419,766 Ordinary Shares, representing approximately 29.75 per cent. of the Company's enlarged issued ordinary share capital. It is expected that the Ordinary Shares issued following this Conversion will commence trading at 8.00am on 6 February 2020.
Following completion of the Conversion, the Company's issued share capital will consist of 145,955,982 ordinary shares of 1 penny each. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
The Directors of the Company accept responsibility for the contents of this announcement.
-ENDS-
For further information, please contact:
IQ-AI Limited Trevor Brown/Vinod Kaushal/Qu Li Tel: 020 7469 0930 |
Peterhouse Capital Limited (Financial Adviser and Broker) Lucy Williams/Heena Karani Tel: 020 7220 9797 |
About IQ-AILtd
IQ-AI, Ltd, the parent company of StoneChecker® and Imaging Biometrics®, is focused on advanced and state of the art medical software and services. (IQ-AI.ltd). Imaging Biometrics develops and provides visualization and analytical solutions that enable clinicians to better diagnose and treat diseases with greater confidence. Through close collaboration with researchers and clinicians, sophisticated advancements are translated into platform-independent software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualization software seamlessly integrates into routine workflows. Please visit www.imagingbiometrics.comfor further information.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
| London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply. |
| ©2014London Stock Exchange plc. All rights reserved |
Conversion of Loan Notes - Correction - RNS
Attachments
- Original document
- Permalink
Disclaimer
IQ-AI Limited published this content on 05 February 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 February 2020 16:35:09 UTC
